Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Next Berlin Patient' Adds to Small but Growing Number of People Cured of HIV

2.

According to JAMA, statin use may increase cancer-related survival in breast cancer patients.

3.

How a California Oncologist Making $850k Spends Money

4.

iPSC-based vaccines: A new hope for preventing and treating colorectal cancer

5.

Alkem introduces cetuximab under the trade name Cetuxa in India.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot